Nurse practitioners can prescribe controlled substances in all 50 states. What changes from one NP to the next is how independently they can do it, which schedules they can reach, and what has to be in place first. Three variables control the answer: the NP’s federal DEA registration, the practice authority granted by their state license, and the schedule of the drug involved.
The Federal Baseline
Before writing a single controlled substance prescription, an NP needs an active Drug Enforcement Administration registration. The DEA classifies nurse practitioners as “mid-level practitioners,” alongside physician assistants, nurse midwives, and nurse anesthetists.1Diversion Control Division | DEA. Mid-Level Practitioners Authorization by State Registration costs $888 for a three-year cycle.2Federal Register. Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants The DEA will not issue that registration unless the NP is already authorized to prescribe controlled substances under the laws of the state where they practice, so state licensure comes first.
Since June 2023, every DEA registrant except veterinarians must also attest to completing at least eight hours of training on treating patients with opioid or other substance use disorders. This is a one-time requirement under the Mainstreaming Addiction Treatment (MATE) Act, and the DEA checks for it on any new application or renewal.3Diversion Control Division | DEA. Opioid Use Disorder – MATE Act Q and A NPs who completed qualifying coursework during their graduate program within the past five years can count that toward the eight hours.
Nearly every prescriber also needs a National Provider Identifier, the 10-digit number that appears on prescriptions and insurance claims. Pharmacies and Part D plans require an individual NPI on each prescription, and failing to obtain one can be treated as noncompliance with federal regulations.4CMS. NPI Requirements for Prescribers Many states add a separate state-level controlled substance license or registration on top of the DEA number, so an NP should check with their state board of nursing and state pharmacy or narcotics agency before assuming federal credentials alone are enough.
What State Practice Authority Changes
State laws sort NPs into three practice categories, and this is where independence varies most.5National Conference of State Legislatures. Nurse Practitioner Practice and Prescriptive Authority
In full practice authority states, NPs can evaluate patients, diagnose, and prescribe Schedule II through V controlled substances without any physician oversight. A growing majority of states now follow this model.
In reduced practice authority states, the NP still prescribes controlled substances, but only under a collaborative practice agreement with a physician. The agreement defines what the NP can prescribe, how often the physician reviews charts, and how the physician stays available for consultation. An expired or incomplete agreement can render every controlled substance prescription written during the gap technically unauthorized, which creates liability for both the NP and the collaborating physician.
Restricted practice states go further. NPs may need direct physician supervision, and some states limit which schedules an NP can prescribe or cap the supply of certain drugs to a few days.
These categories are not static. The trend over the past decade has moved toward greater independence, and states update their rules regularly. An NP relocating should verify the new state’s current requirements before prescribing, because a collaborative agreement that was unnecessary in one state can be mandatory in the next.
Which Schedules and How Refills Work
Federal law divides controlled substances into five schedules based on abuse potential and accepted medical use. Schedule I substances, such as heroin and LSD, have no accepted medical use and cannot be prescribed by anyone in a clinical setting. Schedules II through V have recognized medical uses, with Schedule II carrying the highest abuse potential and Schedule V the lowest.6Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances
Refill rules tighten as the schedule number goes down. Schedule II prescriptions, which include oxycodone, fentanyl, methylphenidate, and amphetamine salts, cannot be refilled at all under federal law. A patient who needs more requires a new prescription each time. Schedule III and IV medications, such as testosterone, certain codeine combinations, and benzodiazepines, can be refilled up to five times within six months from the date the prescription was written.7GovInfo. 21 USC 829 – Prescriptions
State law can narrow the federal rules. An NP might be federally authorized across all five schedules but find their state restricts Schedule II prescribing to specific situations, requires additional documentation, or caps quantities per visit. When federal and state rules differ, the more restrictive one controls.
Telehealth Prescribing Through 2026
The Ryan Haight Act normally requires at least one in-person evaluation before a practitioner can prescribe controlled substances remotely. The DEA suspended that requirement during the COVID-19 public health emergency and has extended the flexibility several times since. Under the current temporary rule, DEA-registered practitioners including NPs can prescribe Schedule II through V controlled substances via telehealth without a prior in-person visit through December 31, 2026.8Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
Conditions still apply. The prescription must be for a legitimate medical purpose, issued in the normal course of professional practice, and the appointment must use a real-time audio-visual system. All standard federal prescription requirements remain in force.9HHS.gov. HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026 Permanent telehealth prescribing rules are in development but have not been finalized. When the temporary rule expires, the in-person evaluation requirement could snap back into effect.
Buprenorphine After the X-Waiver
Prescribing buprenorphine for opioid use disorder used to require a separate DEA waiver, extra training hours, and patient caps. The Consolidated Appropriations Act of 2023 eliminated that waiver. Any practitioner with a current DEA registration that includes Schedule III authority, which covers most NPs, can now prescribe buprenorphine for opioid use disorder without a separate application, patient limit, or additional certification, provided state law permits it.10SAMHSA. Waiver Elimination (MAT Act) The eight-hour MATE Act training still applies, but the old X-waiver process is gone.
Where Prescribing Authority Goes Wrong
Most states operate a Prescription Drug Monitoring Program, an electronic database tracking controlled substance prescriptions filled within the state. Many states require prescribers to check the PDMP before writing a controlled substance prescription, though the trigger varies: some states mandate a check before every prescription, others only for initial prescriptions or specific schedules. Most state PDMPs also connect to a national data-sharing network, so an NP can often see prescriptions filled in neighboring states. Failing to check when required is itself a violation that can trigger disciplinary action, separate from any patient harm.
The DEA can suspend or revoke an NP’s registration for issuing prescriptions that are not for a legitimate medical purpose, for felony convictions related to controlled substances, or for conduct the agency determines is inconsistent with the public interest. In cases involving an imminent danger to public health, the DEA can suspend a registration immediately, before any hearing.11Drug Enforcement Administration. Practitioner’s Manual
State nursing boards act independently, imposing formal reprimand, probation with practice restrictions, suspension, or revocation. The two systems are linked. Losing state licensure triggers loss of DEA registration, since federal registration depends on valid state authorization. If the DEA revokes the registration, the NP can no longer prescribe controlled substances regardless of what the state license still says.